Stereotactic Body Radiation Therapy (SBRT) Post Prostatectomy

Official Title

Post-Prostatectomy Linac-Based Ultrahypofractionated Radiation Therapy for Patients With Localized Prostate Cancer: A Treatment Feasibility and Outcomes Multicentre Study

Summary:

This phase I study will assess the toxicity profile and efficacy of SBRT (Stereotactic body radiation therapy) in patients with localized prostate cancer who are considered candidates for post-prostatectomy radiation.

Trial Description

Primary Outcome:

• Early Adverse Events/toxicities experience by Participants

Secondary Outcome:

• Late Adverse Events/toxicities experienced by Participants
• Quality of Life of participants using the Expanded Prostate Cancer Index Composite questionnaire
• Biochemical disease-free survival
• Health Utilities using The Patient-Oriented Prostate Utility Scale
• Health Utilities using EuroQol- 5 Dimension Questionnaire

Radical prostatectomy is a common treatment for localized prostate cancer, patients with a detectable and/or rising PSA after radical prostatectomy may be offered radiation. An increasing number of patients are being referred post-operatively for radiation therapy, which creates an added burden on radiation therapy departments. Therefore, a strategy that could potentially decrease the number of radiation therapy fractions, yet maintain its efficacy, would be highly desirable for patient convenience, cost saving, and resource utilization as long as the toxicity profile is acceptable. This study will be conducted to asses the toxicity and efficacy of Stereotactic body radiation therapy (SBRT) in post-prostatectomy patients.

View this trial on ClinicalTrials.gov